

2cureX invites to an investor meeting in Stockholm on May 15th, 2019

2cureX AB ("2cureX") hereby invites shareholders and the public to attend an investor meeting in Stockholm. The company will present the ongoing operations, the way forward for 2cureX and the offer for the company's ongoing rights issue. The investor meeting is held at Scandic Klara in Stockholm and the entry starts at 11:30. Lunch and refreshments will be served in conjunction with the investor meeting. The meeting is organised together with OmniCar Holding AB and Sedermera Fondkommission.

To attend the investor meeting on May 15th, 2019, please register here:

<https://sedermera.se/sv/evenemang/2019-05-15/investerartraff-med-2curex-och-omnicar-i-stockholm>

2cureX will also present its business and offering at Öresundsdagen on May 20th, 2019. Öresundsdagen is a cooperation event between Sedermera Fondkommission and Aktiespararna and at the event some of the most promising listed SME companies present their business and network with investors as well as equity funds. To meet 2cureX and attend Öresundsdagen, please register here:

<https://sedermera.se/sv/evenemang/2019-05-20/sedermeradagen-malmo>

Certified Adviser

Sedermera Fondkommission

E-mail: ca@sedermera.se

Phone: +46 40 615 14 15

For more information about 2cureX:

Ole Thastrup, Chief Executive Officer

E-mail: ot@2curex.com

Phone: +45 22 11 53 99

www.2curex.com

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient's tumour. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical studies are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol "2CUREX").